Author: Francescangeli, Federica; De Angelis, Maria Laura; Baiocchi, Marta; Rossi, Rachele; Biffoni, Mauro; Zeuner, Ann
Title: COVID-19–Induced Modifications in the Tumor Microenvironment: Do They Affect Cancer Reawakening and Metastatic Relapse? Cord-id: i6ijgdk1 Document date: 2020_10_26
ID: i6ijgdk1
Snippet: Severe coronavirus disease 2019 (COVID-19) causes an uncontrolled activation of the innate immune response, resulting in acute respiratory distress syndrome and systemic inflammation. The effects of COVID-19–induced inflammation on cancer cells and their microenvironment are yet to be elucidated. Here, we formulate the hypothesis that COVID-19–associated inflammation may generate a microenvironment favorable to tumor cell proliferation and particularly to the reawakening of dormant cancer ce
Document: Severe coronavirus disease 2019 (COVID-19) causes an uncontrolled activation of the innate immune response, resulting in acute respiratory distress syndrome and systemic inflammation. The effects of COVID-19–induced inflammation on cancer cells and their microenvironment are yet to be elucidated. Here, we formulate the hypothesis that COVID-19–associated inflammation may generate a microenvironment favorable to tumor cell proliferation and particularly to the reawakening of dormant cancer cells (DCCs). DCCs often survive treatment of primary tumors and populate premetastatic niches in the lungs and other organs, retaining the potential for metastatic outgrowth. DCCs reawakening may be promoted by several events associated to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, including activation of neutrophils and monocytes/macrophages, lymphopenia and an uncontrolled production of pro-inflammatory cytokines. Among pro-inflammatory factors produced during COVID-19, neutrophil extracellular traps (NETs) released by activated neutrophils have been specifically shown to activate premetastatic cancer cells disseminated in the lungs, suggesting they may be involved in DCCs reawakening in COVID-19 patients. If confirmed by further studies, the links between COVID-19, DCCs reactivation and tumor relapse may support the use of specific anti-inflammatory and anti-metastatic therapies in patients with COVID-19 and an active or previous cancer.
Search related documents:
Co phrase search for related documents- acute infection and long term management: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute infection and lung disseminate: 1
- acute infection and lung resident: 1, 2, 3, 4
- acute infection and lymphocyte activity: 1, 2
- acute infection and lymphocyte apoptosis: 1, 2, 3, 4
- acute infection and lymphocyte death: 1, 2, 3, 4
- acute infection and lymphocyte recruitment: 1
- acute infection and lymphocytic infiltration: 1, 2, 3, 4, 5
- acute infection and lymphopenia cause: 1, 2, 3
- acute infection and macrophage inflammatory protein: 1, 2, 3, 4, 5
- acute respiratory distress and additional cytokine: 1
- acute respiratory distress and additional drug: 1
- acute respiratory distress and long term effect: 1
- acute respiratory distress and long term management: 1, 2, 3, 4, 5, 6
- acute respiratory distress and lung resident: 1, 2, 3, 4, 5, 6
- acute respiratory distress and lymphocyte activity: 1
- acute respiratory distress and lymphocyte death: 1, 2, 3
- acute respiratory distress and lymphocytic infiltration: 1, 2, 3
- acute respiratory distress and lymphopenia result: 1
Co phrase search for related documents, hyperlinks ordered by date